Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
- 1 March 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (5) , 1098-1105
Abstract
Purpose: Recent developments in rare-cell technology have led to improved blood-based assays that allow for the reliable detection, enumeration, and more recently, genomic profiling of circulating tumor cells (CTC). We evaluated two different approaches for enumeration of CTCs in a prospective therapeutic study of patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: The CellSearch system, a commercially available and U.S. Food and Drug Administration (FDA)–cleared assay for CTC enumeration, and IE/FC, an alternative method using EPCAM-based immunomagnetic enrichment and flow cytometry that maintains cell viability, were used to enumerate CTCs in the blood of patients with metastatic TNBC. CTC numbers were assessed at baseline and 7 to 14 days after initiation of therapy with cetuximab ± carboplatin in a phase II multicenter clinical trial (TBCRC 001). Results: CTC numbers from two methods were significantly correlated at baseline (r = 0.62) and at 7 to 14 days (r = 0.53). Baseline CTCs showed no association with time-to-progression (TTP), whereas CTCs at 7 to 14 days were significantly correlated with TTP (CellSearch P = 0.02; IE/FC P = 0.03). CTCs at both time points were significantly associated with overall survival (OS) [CellSearch: baseline (P = 0.0001) and 7 to 14 days (P < 0.0001); IE/FC: baseline (P = 0.0009) and 7 to 14 days (P = 0.0086)]. Conclusions: Our findings demonstrate that CTC enumeration by two different assays was highly concordant. In addition, results of both assays were significantly correlated with TTP and OS in patients with TNBC. The IE/FC method is also easily adapted to isolation of pure populations of CTCs for genomic profiling. Clin Cancer Res; 21(5); 1098–105. ©2014 AACR.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Considerations in the development of circulating tumor cell technology for clinical useJournal of Translational Medicine, 2012
- Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancerBMC Cancer, 2012
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAnnals of Oncology, 2011
- High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patientsAnnals of Oncology, 2011
- Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancerBreast Cancer, 2009
- Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor CellsJNCI: Journal of the National Cancer Institute, 2009
- Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implicationsAnnals of Oncology, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004